Vitae Pharmaceuticals (VTAE) PT Raised to $23 at Wedbush
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
JMP Securities Upgrades Vitae Pharmaceuticals (VTAE) to Market Outperform
March 17, 2016 9:33 AM EDTJMP Securities upgraded Vitae Pharmaceuticals (NASDAQ: VTAE) from Market Perform to Market Outperform.
For an analyst ratings summary and ratings history on Vitae Pharmaceuticals click here. For more ratings news on Vitae Pharmaceuticals click here.
Shares of Vitae Pharmaceuticals closed at $4.11 yesterday.
... MoreStifel Upgrades Vitae Pharmaceuticals (VTAE) to Buy, $15 PT
March 17, 2016 6:27 AM EDTStifel upgraded Vitae Pharmaceuticals (NASDAQ: VTAE) from Hold to Buy with a price target of $15.00, saying 43742 Data shows drug potential is significant, and toxic signal seems manageable.
Analyst Thomas Shrader commented, "Vitae release its eagerly awaited topline data for VTP-43742 and the drug is clearly active.... More
Vitae Pharma (VTAE) Announces Statistically Significant Data from VTP-43742 Phase 2a PoC Trial in Psoriatic Patients
March 16, 2016 4:06 PM EDTVitae Pharmaceuticals, Inc. (Nasdaq: VTAE) announced positive top-line results from its Phase 2a proof-of-concept clinical trial of VTP-43742 in psoriatic patients. VTP-43742 is Vitae's wholly owned, first-in-class, orally active RORt inhibitor with the potential to transform the treatment of multiple autoimmune disorders, including... More
